The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...

Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera, after Pfizer last week ...

Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can ...

Novo Nordisk's surprise bid for Metsera has set the stage for a high-stakes showdown in the obesity drug market, with Pfizer ...

Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U. obesity ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

A bidding war has broken into the open for the obesity-focused Metsera, with Novo Nordisk aiming to outbid Pfizer for the ...

The Danish pharma was rumored to be a bidder in the process to acquire Metsera earlier this year, which Pfizer ultimately won ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...